Trexquant Investment LP Takes Position in Celldex Therapeutics, Inc. $CLDX

Key Points

• Trexquant Investment LP has acquired a new stake in Celldex Therapeutics, Inc., purchasing 78,210 shares valued at approximately $1.42 million.
• Multiple large investors are increasing or acquiring positions in Celldex Therapeutics, indicating growing interest in the biopharmaceutical company.
• Analysts have recently adjusted their price targets for Celldex Therapeutics, with a consensus average price target of $46.67 and a rating of "Moderate Buy."

Trexquant Investment LP bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 78,210 shares of the biopharmaceutical company's stock, valued at approximately $1,420,000. Trexquant Investment LP owned approximately 0.12% of Celldex Therapeutics as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Deutsche Bank AG raised its stake in shares of Celldex Therapeutics by 13.8% in the 1st quarter. Deutsche Bank AG now owns 138,289 shares of the biopharmaceutical company's stock valued at $2,510,000 after purchasing an additional 16,788 shares in the last quarter. Northern Trust Corp grew its position in shares of Celldex Therapeutics by 6.2% during the 4th quarter. Northern Trust Corp now owns 597,605 shares of the biopharmaceutical company's stock valued at $15,101,000 after buying an additional 34,885 shares during the last quarter. Rafferty Asset Management LLC grew its position in shares of Celldex Therapeutics by 67.6% during the 4th quarter. Rafferty Asset Management LLC now owns 152,454 shares of the biopharmaceutical company's stock valued at $3,853,000 after buying an additional 61,464 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Celldex Therapeutics during the 4th quarter valued at about $835,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Celldex Therapeutics during the 1st quarter valued at about $1,131,000.

Celldex Therapeutics Stock Up 1.0%

NASDAQ CLDX traded up $0.24 on Thursday, hitting $25.20. The stock had a trading volume of 1,135,084 shares, compared to its average volume of 1,579,410. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $47.00. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -8.37 and a beta of 1.19. The company's 50-day moving average is $22.70 and its two-hundred day moving average is $20.71.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.01. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. The firm had revenue of $0.73 million during the quarter, compared to analysts' expectations of $1.13 million. On average, sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CLDX has been the subject of a number of recent research reports. HC Wainwright lowered their price objective on shares of Celldex Therapeutics from $50.00 to $42.00 and set a "buy" rating for the company in a research report on Wednesday, August 20th. Wells Fargo & Company lowered their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating for the company in a research report on Wednesday, August 20th. Citigroup lowered their price objective on shares of Celldex Therapeutics from $56.00 to $48.00 and set a "buy" rating for the company in a research report on Wednesday, August 20th. Finally, Canaccord Genuity Group lowered their price objective on shares of Celldex Therapeutics from $64.00 to $62.00 and set a "buy" rating for the company in a research report on Wednesday, August 20th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $46.67.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.